DIADIA0.62%
SPYSPY1.32%
QQQQQQ2.25%
Trending
Top trending tickerQQQQQQ2.25%
BULLBULL0.85%
BMNRBMNR10.91%
SPYSPY1.32%
MUMU10.74%
IWMIWM1.73%
WMTWMT6.01%
BTCBTC3.45%
MSTRMSTR6.07%
NIONIO7.57%
Top trending tickerQQQQQQ2.25%
BULLBULL0.85%
BMNRBMNR10.91%
SPYSPY1.32%
MUMU10.74%
IWMIWM1.73%
WMTWMT6.01%
BTCBTC3.45%
MSTRMSTR6.07%
NIONIO7.57%
homeSymbolFEMY

FEMY
Femasys Inc

4,178
Mkt Cap
$44.47M
Volume
3.18M
52W High
$1.80
52W Low
$0.3067
PE Ratio
-1.05
FEMY Fundamentals
Price
$0.8003
Prev Close
$0.7589
Open
$0.805
50D MA
$0.6055
Beta
0.78
Avg. Volume
12.77M
EPS (Annual)
-$0.845
P/B
7.88
Rev/Employee
$22,945.18
Loading...
Loading...

Feed

News

Sentiment

Fundamentals

Info

News
all
press releases
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing
Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.
Stocktwits·17d ago
News Placeholder
More News
News Placeholder
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Femasys (FEMY) delivered earnings and revenue surprises of +11.11% and -48.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.
Stocktwits·6mo ago
News Placeholder
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
chainwire·7mo ago
News Placeholder
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic
The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.
Stocktwits·8mo ago
News Placeholder
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says
Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market. read more...
Benzinga·1y ago
News Placeholder
Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential
Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Femasys (FEMY Research Report). The associated price target remains the...
TipRanks Financial Blog·2y ago
News Placeholder
Femasys price target raised by $2 at H.C. Wainwright, here's why
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago

Latest FEMY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.